2025-05-09T08:40:33+00:00 2024-06-30 346565596 ERNST & YOUNG US LLP 2323 VICTORY AVENUE DALLAS TX 75219 990 2023-07-01 510197108 SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE SANF 8586463100 10901 NORTH TORREY PINES ROAD LA JOLLA CA 92037 MICHAEL JONES CFO & TREASURER 8587955244 2025-05-09 true Patrick Shields P01508556 2149698000 2025-05-08 2023 2025-03-06 01:10:19Z David Brenner 10901 NORTH TORREY PINES ROAD LA JOLLA CA 92037 199653255 false X WWW.SBPDISCOVERY.ORG X 1976 CA SEE SCHEDULE O 16 14 594 16 1168761 0 104423511 107001067 1012265 669975 5926237 12533478 5857091 3067961 117219104 123272481 0 0 0 0 58193349 63300127 0 0 1804005 45204369 47874465 103397718 111174592 13821386 12097889 308605226 326353986 65071238 58142392 243533988 268211594 SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE'S MISSION IS TO ADVANCE THE BIOMEDICAL SCIENCES BY CULTIVATING THE NEXT GENERATION OF SCIENTIFIC LEADERS, PROVIDING MEANINGFUL OPPORTUNITIES FOR RESEARCHERS OF ALL BACKGROUNDS TO LEARN, INNOVATE, AND MAKE BREAKTHROUGH DISCOVERIES THAT IMPROVE HUMAN HEALTH. false false 90729383 0 776452 See Schedule O 90729383 true true false true false false false false true true true false false true true true false false false true false false false true false false false false true true false false false false false false false false false false false false false false false false false false false true 194 0 true 594 true true true false false false false true true false false false false false false false false X 16 14 false false false false false false false true true false false true true true true true true true true false CA CO CT DC FL GA AL HI IL KS KY ME MD MA MI MN MS MO NH NJ NM NY NC ND OH OR PA RI SC TN UT VA AR WI X X MICHAEL JONES 8586463100 10901 NORTH TORREY PINES RD LA JOLLA CA 92037 DAVID BRENNER MD CEO AND PRESIDENT 50.0 0.0 X X 984345 0 327443 DONALD B KEARNS MD VICE CHAIRMAN 1.0 0.0 X X 0 0 0 WILLIAM GERHART CHAIRMAN 1.0 0.0 X X 0 0 0 DANIEL J EPSTEIN TRUSTEE 1.0 0.0 X 0 0 0 DAVID L SZEKERES JD TRUSTEE 1.0 0.0 X 0 0 0 DAVID W DOWN TRUSTEE 1.0 0.0 X 0 0 0 DOUGLAS H OBENSHAIN TRUSTEE 1.0 0.0 X 0 0 0 JAMES C BLAIR PHD TRUSTEE (PART YEAR) 1.0 0.0 X 0 0 0 JAMES M MYERS TRUSTEE (PART YEAR) 1.0 0.0 X 0 0 0 KATHERINE CHAPIN TRUSTEE 1.0 0.0 X 0 0 0 KAZUMI SHIOSAKI PHD TRUSTEE 1.0 0.0 X 0 0 0 LONNA J WILLIAMS STOLPER TRUSTEE 1.0 0.0 X 0 0 0 LORI MOORE TRUSTEE 1.0 0.0 X 0 0 0 MICHAEL R CUNNINGHAM TRUSTEE 1.0 0.0 X 0 0 0 NICHOLAS COSFORD PROFESSOR & TRUSTEE 50.0 0.0 X 244128 0 68484 STUART A TANZ TRUSTEE 1.0 0.0 X 0 0 0 TED ROTH TRUSTEE 1.0 0.0 X 0 0 0 WILLIAM A ROPER TRUSTEE 1.0 0.0 X 0 0 0 ADRIENNE CROWN JD GENERAL COUNSEL & SECRETARY 50.0 0.0 X 360490 0 48673 ROBIN RYAN CFO & TREASURER 50.0 0.0 X 458690 0 48299 CARL WARE PHD CENTER DIRECTOR, IIDC 50.0 0.0 X 454389 0 63702 KRISTIINA VUORI MD PHD PROFESSOR 50.0 0.0 X 601208 0 60610 MICHAEL JACKSON PHD DRUG DISCOVERY & DEV, SR VP 50.0 0.0 X 447238 0 58573 RANDAL KAUFMAN PHD PROGRAM DIRECTOR 50.0 0.0 X 402033 0 75955 ZE'EV RONAI PHD CENTER DIRECTOR 50.0 0.0 X 497532 0 63660 C RANDAL MILLS PHD FORMER CEO 0.0 0.0 X 341250 0 0 4791303 0 815399 139 true true false Universal Protection Service LP PO Box 31001-2374 Pasadena CA 921102374 Building Security Services 326043 Wilson Sonsini Goodrich & Rosati PO Box 742866 Los Angeles CA 900742866 Legal Services 310415 Deloitte & Touche LLP PO Box 844708 Dallas TX 75284 Professional Services 269260 JAGGAER LLC PO BOX 952218 DALLAS TX 753952218 Procurement Services 229200 Constangy Brooks Smith & Porphete LLP PO Box 102476 Atlanta GA 303680476 Legal Services 201763 8 0 0 276700 69821069 36903298 4101 107001067 Shared Services Revenue 541990 669975 669975 0 0 0 0 0 0 669975 6757453 7850 6749603 0 0 1515072 1515072 318300 0 318300 0 318300 318300 81702000 75925975 5776025 0 5776025 5776025 422000 276700 454799 -32799 -32799 Research 541700 1160911 1160911 Equipment Proceeds 541990 34563 34563 Sale of Reagents 541990 65914 65914 6000 6000 0 0 1267388 123272481 776452 1168761 14326201 0 0 0 0 0 0 0 0 1465150 32500 1286400 146250 341250 0 341250 0 47639883 38317433 8456820 865630 3096876 2417032 625235 54609 7624582 5886415 1376517 361650 3132386 2412870 653549 65967 809508 273878 453260 82370 928176 62346 855330 10500 421627 0 421627 0 1500 0 1500 0 0 0 679787 0 679787 0 861908 569281 243903 48724 975 0 975 0 5634672 5076466 540521 17685 1689633 1215046 441169 33418 0 0 0 0 6575946 6149262 401887 24797 361891 328382 30749 2760 0 0 0 0 1004212 662268 338044 3900 1151762 1077703 69682 4377 0 0 0 0 5369141 5023905 324833 20403 230910 0 230910 0 RESEARCH SUPPLIES & SVCS 9888051 9887929 3 119 SCIENTIFIC COLLABORATIONS 11008033 11008033 0 0 RECRUITMENT 220928 151902 62615 6411 TUITION FEES 112908 112908 0 0 922897 63824 804638 54435 111174592 90729383 18641204 1804005 0 0 0 0 3884263 3821604 3005 573 8358514 7689710 728432 525718 0 0 0 0 3332786 5645175 318694 372410 9710993 9857014 168830822 117517685 52107305 51313137 193702694 201913843 35094304 44462501 0 1364236 752301 308605226 326353986 14782361 14624878 7432976 5645487 39230617 34979693 0 0 3625284 2892334 65071238 58142392 X 183976210 200481486 59557778 67730108 243533988 268211594 308605226 326353986 12097889 12579717 0 X false true X true true true X 100963692 111444313 82047252 104423511 107001067 505879835 0 0 100963692 111444313 82047252 104423511 107001067 505879835 54196231 451683604 3455907 5237546 7508720 9515640 8590825 34308638 0 0 0 0 0 0 0 0 0 0 0 0 540188473 5202370 0.8362 0.8870 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false false false false false false false false true 1500 1500 false Schedule C, Part II-B, Line 1 DETAILED DESCRIPTION OF THE LOBBYING ACTIVITY DUES TO AN ASSOCIATION OF INDEPENDENT RESEARCH INSTITUTES, OF WHICH A PORTION IS USED FOR LOBBYING. 21212422 1002100 2217901 937725 23494698 20548272 2825 1615074 953749 21212422 23536441 1805 -2492894 497080 20548272 19914852 3687 4470604 852702 23536441 29814541 1005 724999 10625693 19914852 0.02 0.62 0.36 false false 12758161 12758161 92588616 63223124 29365492 28337 28337 63455708 54294561 9161147 51313137 PRIVATE EQUITY LPS 12392960 F TOTAL RETURN HEDGE FUNDS 930363 F SELECT EQUITY FUNDS 25772881 F HC ALTERNATIVE CREDIT OPP 5366297 F 44462501 OPERATING LEASE LIABILITIES 752301 FINANCE LEASE LIABILITIES 2140033 2892334 X 136010000 12579717 837908 0 13417625 122592375 679787 319 680106 123272481 111333000 837908 0 837908 110495092 679787 612 680399 111175491 Schedule D, Part V, Line 4 Intended uses of endowment funds INTENDED USES OF THE ORGANIZATION'S ENDOWMENT FUNDS: THE INSTITUTE'S ENDOWMENT FUNDS ARE ESTABLISHED FOR VARIOUS PURPOSES: SCIENTIFIC RESEARCH, CEO CHAIR, PRESIDENTIAL CHAIR, CANCER AND NEUROSCIENCE LEADERSHIP CHAIRS, AND UNRESTRICTED AS TO INCOME. Schedule D, Part X, Line 2 FIN 48 (ASC 740) footnote THE INSTITUTE HAS NO MATERIAL DEFERRED TAX ASSETS OR DEFERRED TAX LIABILITIES REOCREDED AS OF JUNE 30, 2024 AND 2023. THE INSTITUTE DID NOT RECOGNIZE A CHANGE IN LIABILITY FOR UNRECOGNIZED TAX BENEFITS (THE DIFFERENCE BETWEEN A TAX POSITION TAKEN, OR EXPECTED TO BE TAKEN, IN A TAX RETURN AND THE BENEFIT RECOGNIZED AND MEASURED IN THE FINANCIAL STATEMENTS). THERE WERE NO LIABILTITIES FOR UNRECOGNIZED TAX BENEFITS AT JUNE 30, 2024 AND 2023. Schedule D, Part XI, Line 4(b) Other revenues in form 990 not in audited financial statements ROUNDING - 319 Schedule D, Part XII, Line 4(b) Other expenses in form 990 not in audited financial statements ROUNDING - 612 Europe (Including Iceland and Greenland) Speaking engagements,Conference Travel ACTIVITY IN ALL REGIONS IS EMPLOYEES ATTENDING AND/OR SPEAKING AT SCIENTIFIC CONFERENCES AND COLLABORATIONS. 120012 East Asia and the Pacific Speaking engagements,Conference Travel ACTIVITY IN ALL REGIONS IS EMPLOYEES ATTENDING AND/OR SPEAKING AT SCIENTIFIC CONFERENCES AND COLLABORATIONS. 15619 Central America and the Caribbean Speaking engagements,Conference Travel ACTIVITY IN ALL REGIONS IS EMPLOYEES ATTENDING AND/OR SPEAKING AT SCIENTIFIC CONFERENCES AND COLLABORATIONS. 0 South America Speaking engagements,Conference Travel ACTIVITY IN ALL REGIONS IS EMPLOYEES ATTENDING AND/OR SPEAKING AT SCIENTIFIC CONFERENCES AND COLLABORATIONS. 19964 North America (Canada & Mexico only) Speaking engagements,Conference Travel ACTIVITY IN ALL REGIONS IS EMPLOYEES ATTENDING AND/OR SPEAKING AT SCIENTIFIC CONFERENCES AND COLLABORATIONS. 47 Central America and the Caribbean Investments 18689620 Middle East and North Africa Speaking engagements,Conference Travel ACTIVITY IN ALL REGIONS IS EMPLOYEES ATTENDING AND/OR SPEAKING AT SCIENTIFIC CONFERENCES AND COLLABORATIONS. 4743 0 0 0 0 0 0 18850005 0 18850005 true false true true true false Schedule F, Part I, Line 3 Method used to account for expenditures on org's financial statements CENTRAL AMERICA AND THE CARIBBEAN-Accrual,; EAST ASIA AND THE PACIFIC-Accrual; EUROPE (INCLUDING ICELAND AND GREENLAND)-Accrual; MIDDLE EAST AND NORTH AFRICA-Accrual; NORTH AMERICA (CANADA & MEXICO ONLY)-Accrual; SOUTH AMERICA-Accrual Gala 698700 276700 422000 186427 23750 244622 0 0 698700 276700 422000 186427 23750 244622 454799 -32799 X X true true X X X X X X true true false false false false false true false DAVID BRENNER MD CEO AND PRESIDENT 974234 0 0 0 10111 0 312500 0 14943 0 1311788 0 0 0 C RANDAL MILLS PHD FORMER CEO 0 0 0 0 341250 0 0 0 0 0 341250 0 0 0 NICHOLAS COSFORD PROFESSOR & TRUSTEE 240544 0 0 0 3584 0 24270 0 44214 0 312612 0 0 0 ROBIN RYAN CFO & TREASURER 451617 0 0 0 7073 0 33000 0 15299 0 506989 0 0 0 ADRIENNE CROWN JD GENERAL COUNSEL & SECRETARY 357860 0 0 0 2630 0 33000 0 15673 0 409163 0 0 0 ZE'EV RONAI PHD CENTER DIRECTOR 437537 0 50000 0 9995 0 33000 0 30660 0 561192 0 0 0 MICHAEL JACKSON PHD DRUG DISCOVERY & DEV, SR VP 441089 0 0 0 6149 0 33000 0 25573 0 505811 0 0 0 KRISTIINA VUORI MD PHD PROFESSOR 598654 0 0 0 2554 0 33000 0 27610 0 661818 0 0 0 CARL WARE PHD CENTER DIRECTOR, IIDC 423954 0 0 0 30435 0 33000 0 30702 0 518091 0 0 0 RANDAL KAUFMAN PHD PROGRAM DIRECTOR 386854 0 0 0 15179 0 33000 0 42955 0 477988 0 0 0 Schedule J, Part I, Line 1a First-class or charter travel FIRST CLASS TRAVEL IS GENERALLY NOT PERMITTED, EXCEPT UNDER VERY LIMITED AND RARE CIRCUMSTANCES AND CONDITIONS, SUCH AS A MEDICAL CONDITION REQUIREMENT AND URGENT CIRCUMSTANCES. THIS WAS NOT TREATED AS TAXABLE COMPENSATION. Schedule J, Part I, Line 1a Health or social club dues or initiation fees HEALTH OR SOCIAL CLUB DUES ARE NEGOTIATED IN THE HIRING PROCESS FOR CERTAIN EMPLOYEES. THE AMOUNTS WERE TREATED AS TAXABLE COMPENSATION. Schedule J, Part I, Line 4a Severance or change-of-control payment C. RANDAL MILLS, PHD RECEIVED $341,250 IN SEVERANCE AS PART OF HIS SEPARATION AGREEMENT. Schedule J, Part I, Line 4b Supplemental nonqualified retirement plan A RETENTION BONUS WAS SET UP FOR THE PRESIDENT AND CEO, DR. DAVID BRENNER, WHERE VESTING WILL OCCUR THE EARLIEST OF 09/14/27. DISTRIBUTION IS A ONE-TIME LUMP SUM PAYMENT UPON VESTING. Schedule J, Part I, Line 7 Non-fixed payments SOME SENIOR EXECUTIVES HAVE EMPLOYMENT AGREEMENTS STIPULATING A BONUS WILL BE PAID TO THEM PROVIDED CERTAIN GOALS OR ACCOMPLISHMENTS ARE ACHIEVED. Schedule J, Part II, Column (C) RETIREMENT AND OTHER DEFERRED COMPENSATION THE AMOUNT REPORTED IN SCHEDULE J, PART II, COLUMN C INCLUDES THE ACCRUAL OF $300,000 FOR THE PRESIDENT & CEO, DR. DAVID BRENNER FOR A RETENTION BONUS DESCRIBED IN PART I. THE AMOUNT IS NOT VESTED AND IS SUBJECT TO SUBSTANTIAL RISK OF FORFEITURE. A COUNTY OF SAN DIEGO 956000934 79742YAQ5 2015-11-12 61963256 REFINANCE 2006 AND 2012 BONDS WITH ISSUE DATES OF 02/01/2006 AND 11/15/2012 , RESPECTIVELY. false false false A 23210000 0 61963256 0 0 0 289386 0 0 0 61673870 0 2015 true false true true A false true true true true true 0.0131 0.0 0.0131 false false true A false false true false true false false false true A true Schedule K, Part V Different Procedures to Undertake Corrective Action Issuer name: COUNTY OF SAN DIEGO FOR THE BOND ISSUES LISTED IN PART I, THE ALTERNATIVE PERIOD USED FOR THE REPORTING REQUIREMENTS IN THIS SECTION IS THE TWELVE MONTHS ENDED DECEMBER 31, 2024. Form 990, Part I, Line 1 MISSION STATEMENT SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE'S MISSION IS TO ADVANCE THE BIOMEDICAL SCIENCES BY CULTIVATING THE NEXT GENERATION OF SCIENTIFIC LEADERS, PROVIDING MEANINGFUL OPPORTUNITIES FOR RESEARCHERS OF ALL BACKGROUNDS TO LEARN, INNOVATE, AND MAKE BREAKTHROUGH DISCOVERIES THAT IMPROVE HUMAN HEALTH. Form 990, Part III, Line 4a Form 990 - Part III, line 4 Program Service Accomplishments Sanford Burnham Prebys is an independent nonprofit medical research organization dedicated to uncovering the origins of disease and launching bold new strategies that lay the foundation for cures. The institute has deep expertise in fundamental biology highlighted by four disease-focused centers, two technology-enabling centers and four cross-cutting themes; stem cells and regenerative medicine; and the Sanford Children's Health Research Center. Cancer Selected published research How a protein component of nuclear pore complexes regulates development of blood cells and may contribute to myeloid disorders. Maximiliano D' Angelo, PhD, et al. Science Advances. June 5, 2024. How tumor stiffness alters immune cell behavior to escape destruction. Kevin Tharp, PhD, and Kelly Kersten, PhD, et al. Nature Cancer. June 3. 2024. Overlooked lipid connected to ancient cellular pathway with links to cancer. Brooke Emerling, PhD, et al. Science Signaling. May 28, 2024. AI tool predicts responses to cancer therapy using information from each cell of the tumor. Sanju Sinha, PhD, et al. Nature Cancer. Apr 18, 2024. What makes a pathogen antibiotic-resistant? Andrei L. Osterman, PhD, et al. npj Antimicrobials and Resistance. Mar 2, 2024. New genome mapping tool may uncover secrets for treating blood cancers. Kristiina Vuori, MD, PhD, et al. Cancers. Jan 18, 2024. The "Eph" system may pave the way for novel cancer therapies. Elena Pasquale, PhD, et al. Nature Reviews Cancer. Nov 27, 2023. "DNA loops" in pediatric brain tumors double relapse risk. Lukas Chavez, PhD, et al. Nature Genetics. Nov 14, 2023. Copycat nutrient leaves pancreatic tumors starving. Cosimo Commisso, PhD, et al. Nature Cancer. Oct 8, 2023. This sugar kills honeybees-it could also help fight cancer. Hudson Freeze, PhD, et al. eLife. July 17, 2023. Cardiovascular and Muscular Diseases Selected published research New genes implicated in deadly heart defect. Rolf Bodmer, PhD, and George Vogler, PhD, et al. eLife. July 17, 2023. Neurologic Diseases Selected published research Tiny brain bubbles carry complete codes. Jerold Chun, MD, PhD, et al. Cell Reports. Apr 23, 2024. Common HIV treatments may aid Alzheimer's disease patients. Jerold Chun, MD, PhD, et al. Pharmaceuticals. Mar 22, 2024. Similarity between vitamin B12 loss and multiple sclerosis revealed. Jerold Chun, MD, et al. Cell Reports. Dec 8, 2023. Inhibiting an enzyme associated with aging could help damaged nerves regrow and restore strength. Yu Xin Wang, PhD, et al. Science Translational Medicine. Oct 11, 2023. Metabolic and Liver Diseases Selected published research A new 3D bioprinted model offers a novel tool to study common liver disease, and perhaps find an effective treatment. David Brenner, MD, et al. American Journal of Pathology. Dec 27, 2023. How liver cells become scarring, and worse. David Brenner, MD, et al. Cellular and Molecular Gastroenterology and Hepatology. Sept 27, 2023. Cross-cutting Themes New roles for autophagy genes in cellular waste management and aging. Malene Hansen, PhD, et al. Nature Aging. Jan 4. 2024. A potential new weapon against a deadly, drug-resistant bacterial pathogen. Andrei Osterman, PhD, et al. Nature. Jan 3, 2024. Study reveals Zika's shape-shifting machinery-and a possible vulnerability. Alexey Terskikh, PhD, et al. PLOS Pathogens. Nov 27, 2023. Selected Awards and Grants Michael Jackson, PhD, and collaborators at Cedars-Sinai have received a four-year, $2.5 million grant from the National Cancer Institute to target the mutant promoter of TERT, which is associated with an increased risk of acute myeloid leukemia. Tim Huang, PhD, was awarded a five-year, $4.3 million grant from the National Institute on Aging to study the potential therapeutic value of SORLA against Alzheimer's disease and related tauopathies. The research is in collaboration with Kevin Yip, PhD. Sanjeev Ranade, PhD, received a three-year, $752,000 award from Additional Ventures to define neural crest regulatory networks and lineages in outflow tract development. Georg Vogler, PhD, was awarded a 3-year, $142,000 grant from the National Aeronautics and Space Administration (NASA) to study the neurological, cardiac and muscular consequences of living in a deep space environment, using the model organism Drosophila melanogaster (fruit fly). Yu Xin Wang, PhD, received a 1-year, $50,000 award from the Department of Health & Human Services (NIH) to study CODEX multiplex immunofluorescence to detect cellular senescence, part of the Cellular Senescence Network initiative. Jerold Chun, MD, PhD, was awarded a 3-year, $660,000 grant from the Larry L. Hillblom Foundation to continue his research into mosaicism and its contribution to age-related neurological disease. Yu Xin Wang, PhD, received a 1-year, $50,000 award from the Department of Health & Human Services (NIH) to study CODEX multiplex immunofluorescence to detect cellular senescence, part of the Cellular Senescence Network initiative David Brenner, MD, received a 5-year, $1.5 million from the NIH and the Department of Health & Human Services to study how collagen fibers and fragments regulate pancreatic cancer metabolism and growth. Nicholas Cosford, PhD, received a 3-year, $500,000 award from Curebound to further pursue the therapeutic potential of ULK1 inhibitor proteins, which have been shown to be a promising biomarker in predicting prognoses and clinical response to cancer treatments. Cosimo Commisso, PhD, received a 1-year, $195,000 award from Curebound to study ion homeostasis as a new drug target for pancreatic cancer treatments. Maximiliano D'Angelo, PhD, received a 2-year, $300,000 Discovery Boost Grant from the American Cancer Society to further his research on how components of nuclear pore complexes (multiprotein channels that act as gatekeepers to the genome) modulate the anti-tumor immune response and might be used as therapeutic targets. Form 990, Part VI, Line 11b Review of form 990 by governing body PROCESS USED BY MANAGEMENT AND/OR GOVERNING BODY TO REVIEW FORM 990: THE 990 IS PREPARED BY THE FINANCE DEPARTMENT. IT IS REVIEWED BY THE INSTITUTE'S TAX ADVISORS, SELECTED MEMBERS OF MANAGEMENT INCLUDING THE CFO AND AUDIT COMMITTEE, AND PROVIDED TO MEMBERS OF THE BOARD PRIOR TO FILING. Form 990, Part VI, Line 12c Conflict of interest policy DESCRIPTION OF PROCESS TO MONITOR TRANSACTIONS FOR CONFLICT OF INTEREST: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUE HAS A CONFLICT OF INTEREST POLICY THAT REQUIRES ALL TRUSTEES, PRINCIPAL OFFICERS OR MEMBERS OF A COMMITTEE WITH BOARD DELEGATED POWERS TO ANNUALLY CONFIRM THEIR RECEIPT OF THE CONFLICT OF INTEREST POLICY AND DISCLOSE ANY NEW ASSOCIATIONS OR INTEREST THAT MIGHT POTENTIALLY POSE A CONFLICT. THIS IS A WRITTEN CONFIRMATION THAT SHE OR HE READ AND UNDERSTANDS THE CONFLICT OF INTEREST POLICY, WILL ABIDE BY THE CONFLICT OF INTEREST POLICY AND CERTIFIES DISCLOSURE OF ALL INTERESTS OR RELATIONSHIPS THAT MAY POSE CONFLICTS. NEW TRUSTEES RECEIVE TRAINING REGARDING THE INSTITUTE'S CONFLICT OF INTEREST POLICY, WHICH INCLUDES HOW TO IDENTIFY A CONFLICT OF INTEREST AND HOW TO HANDLE POSSIBLE CONFLICTS OF INTEREST WHEN THEY ARISE. THE COMPLIANCE DEPARTMENT REVIEWS EACH OF THE STATEMENTS AND ASSESSES WHETHER AN ACTUAL OR POTENTIAL CONFLICT OF INTEREST EXISTS AND REFERS THE MATTER TO THE BOARD TO WHETHER THE INDIVIDUAL SHOULD BE PROHIBITED FROM CONSIDERATION OF RELATED ITEMS. ANY TRUSTEE, PRINCIPAL OFFICER OR MEMBER OF A COMMITTEE WITH BOARD DELEGATED POWERS WITH A CONFLICT IN A MATTER REQUIRING ACTION BY THE BOARD ARE PROHIBITED FROM PARTICPATING IN THE BOARD'S DELIBERATIONS AND/OR VOTING ON THE PARTICULAR TRANSACTION OR MATTER IN WHICH HE OR SHE HAS AN INTEREST; AND OTHERWISE REFRAIN FROM EXERTING ANY INFLUENCE TO AFFECT A DECISION. HOWEVER, OTHER MEASURES MAY BE REQUIRED, DEPENDING ON THE NATURE OF AND THE ABILITY TO REASONABLY MANAGE A CONFLICT. Form 990, Part VI, Line 15a Process to establish compensation of top management official COMPENSATION FOR THE CEO AND PRESIDENT, CHIEF FINANCIAL OFFICER, AND OTHER KEY EMPLOYEES IS ESTABLISHED ACCORDING TO INSTITUTE POLICIES THAT ARE DESIGNED TO MEET THE IRS STANDARD FOR "REBUTTABLE PRESUMPTION OF REASONABLENESS". THE COMPENSATION COMMITTEE OF THE BOARD OF TRUSTEES, CONSISTING OF AT LEAST THREE INDEPENDENT TRUSTEES, REVIEWS COMPARABILITY DATA AT LEAST EVERY TWO YEARS PROVIDED BY AN INDEPENDENT EXTERNAL CONSULTANT/RESOURCE THAT INCORPORATES AND EVALUATES INSTITUTE DATA AND THAT OF COMPARABLE ORGANIZATIONS AND MARKETS FROM WHICH THE INSTITUTE DRAWS ITS EXECUTIVE TALENT. UTILIZING THIS INFORMATION, THE COMPENSATION COMMITTEE MAKES A DETERMINATION WHETHER THE PROPOSED COMPENSATION IS REASONABLE. THE COMPENSATION COMMITTEE HAS BEEN DELEGATED AUTHORITY BY THE BOARD OF TRUSTEES TO REVIEW AND APPROVE COMPENSATION OF ALL POSITIONS EXCEPT FOR THE CEO. THE CEO'S COMPENSATION PACKAGE IS REVIEWED AND APPROVED INITIALLY BY THE COMPENSATION COMMITTEE AND THEN GOES TO THE EXECUTIVE COMMITTEE FOR FINAL APPROVAL. THE COMPENSATION COMMITTEE CONTEMPORANEOUSLY AND ADEQUATELY DOCUMENTS THE BASIS FOR ITS DETERMINATION AND RECOMMENDATION TO THE EXECUTIVE COMMITTEE. IF APPROVED BY THE EXECUTIVE COMMITTEE, THE CEO COMPENSATION PACKAGE IS THEN IMPLEMENTED AND SUCH DOCUMENTATION IS KEPT IN THE WRITTEN AND ELECTRONIC RECORDS OF THE BOARD OF TRUSTEES. THE PROCESS WAS LAST COMPLETED ON JUNE 27, 2023. THE NEXT REVIEW WILL BE COMPLETED JUNE 2025. Form 990, Part VI, Line 15b Process to establish compensation of other employees SEE ABOVE Form 990, Part VI, Line 19 Required documents available to the public PROCESS FOR MAKING DOCUMENTS AVAILABLE TO THE PUBLIC: DOCUMENTS ARE AVAILABLE UPON REQUEST AND THE INSTITUTE'S TAX FORM 990 IS AVAILABLE ON CHARITY NAVIGATOR AND GUIDESTAR. Form 990, Part VIII, Line 11d Other Miscellaneous Revenue ALL OTHER REVENUE - Total Revenue: 6000, Related or Exempt Function Revenue: 6000, Unrelated Business Revenue: , Revenue Excluded from Tax Under Sections 512, 513, or 514: ; Schedule F, Part I, Line 3 Program Service Activities Sanford Burnham Prebys Medical Discovery Institute does not maintain ongoing operations in foreign jurisdictions. However, the Institute's scientists do travel to various scientific conferences in other countries to share the Institute's scientific discoveries, as well as, to learn from other scientists across the world. Schedule F, Part I, Line 3(e) Type of Service Specific Program Service Activity in all regions is employees attending and/or speaking at scientific conferences and collaborations. Schedule F, Part I, Line 3(f) Accounting Method The accrual method of accounting was used to determine the amounts in Part I, line 3, column F.